Skip to main content


New Theranostic Approaches for Pancreatic Ductal Adenocarcinoma

Tuesday, April 19, 2022

12:00 pm - 1:00 pm

About the Event

Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second leading cause of cancer-related death by 2030. PDAC is one of the predominant (~95%), lethal and highly metastatic forms of pancreatic cancer (PanCa). Recently we have identified a novel trans-membrane mucin MUC13 which is highly over-expressed in ovarian, pancreatic and colon cancers. Our studies have shown dysregulated expression of MUC13 in cancers, including PDAC; however this molecule is still under investigated in PDAC and appears an unmet clinical need. The aberrant expression of MUC13 has been detected in the PDAC patients and correlated with patient’s poor prognosis. Our data also suggest that the aberrant expression of MUC13 is involved in enhancement of tumorigenic and metastasis of PDAC cells and its expression can be influenced by socio-behavioral factors. In this talk, we will discuss how our studies will help in identifying novel targets that can influence the PDAC metastasis and how we can utilize MUC13 to develop more effective treatment and imaging modalities for PDAC.

About the Speaker

The primary research interest of Subhash Chauhan’s, Ph.D., lab is to identify and characterize the diagnostic and therapeutic targets for cancer. This research is aimed for the identification and characterization of biomarkers that aberrantly express or localize in cancer cells to develop new tools for early disease diagnosis. Chauhan’s lab is utilizing genomics and proteomics approaches for identification of novel early diagnostic markers.



Courtney Hunt, Ph.D.
Director, Strategic Research Development